Icahn Confirms Intention to Nominate Three Directors at Biogen

    NEW YORK, Jan. 28 /PRNewswire/ -- Carl Icahn confirmed today that
 entities affiliated with him have given notice to Biogen Idec that they
 intend to nominate three persons at Biogen's forthcoming 2008 Annual
 Meeting of Stockholders to serve as directors of Biogen. Biogen currently
 has a staggered board of twelve directors, and there are four directorships
 up for election this year.
 
     Mr. Icahn stated that "We are taking this action because we believe
 that Biogen's recent purported attempt to find a suitor was not conducted
 in a way to enhance the success of the endeavor. We believe that the
 process was flawed in a number of key respects and that the process was run
 to placate us and other large shareholders who we believe asked for Biogen
 to find a buyer.
 
     "It has been reported in the press that Biogen refused to allow
 potential bidders to talk to Elan Pharmaceuticals, Biogen's partner on the
 key pharmaceutical product Tysabri. Elan has some change-of-control rights
 on Tysabri. Although Elan has indicated that they would not invoke
 change-of-control rights, obviously, any prospective bidder would want to
 talk to Elan directly about change-of-control issues as well as discuss the
 growth trajectory for Tysabri. Incredibly, Biogen prevented any bidder from
 talking to Elan about anything unless they made a 'binding proposal' as
 reported in the Financial Times on January 21, 2008."
 
     Mr. Icahn also stated, "We also believe that the confidentiality
 agreement was so restrictive that certain potential bidders were not able
 to sign the agreement and therefore were not able to participate in the
 bidding."
 
     Mr. Icahn also pointed out that after Biogen announced that it was
 ending the sale process, Jim Mullen, CEO of Biogen, was quoted in the
 Financial Times as saying that Biogen might make a large scale acquisition.
 He is quoted as saying, "We could spend 10 billion dollars." Mr. Icahn
 indicated that he is quite concerned and believes all Biogen shareholders
 should share his concern that Biogen may attempt to make an acquisition for
 the purpose of making it unattractive to, or reducing the number of, future
 potential buyers. In fact, Mr. Icahn noted that The Times of London
 reported on Saturday that Biogen may be considering a bid for a European
 biotech company. Mr. Icahn stressed that he reserved the right to oppose
 any "toxic" transactions by all available means.
 
     The slate of directors to be nominated by Mr. Icahn and his affiliates
 consists of Alexander J. Denner whose principal occupation is Managing
 Director of entities controlled by Mr. Icahn that manage private investment
 funds, Professor Anne B. Young, who is Julianne Dorn Professor of Neurology
 at Harvard Medical School and Chief, Neurology Service at Massachusetts
 General Hospital, and Professor Richard C. Mulligan, who is Mallinckrodt
 Professor of Genetics at Harvard Medical School, and Director of the
 Harvard Gene Therapy Initiative.
 
     "We determined to run a slate of three directors to ensure that if the
 slate were to be elected and Biogen's management failed to act to enhance
 shareholder value, shareholders would have the opportunity to elect
 sufficient new directors in 2009 who, together with our slate of 2008
 directors, would constitute a majority of the board."
 
     SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER
 DOCUMENTS RELATED TO SOLICITATION OF PROXIES BY MR. ICAHN AND HIS
 AFFILIATES FROM THE STOCKHOLDERS OF BIOGEN IDEC INC. WHEN AND IF THEY
 BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. THEY ARE
 OR WILL BE AVAILABLE WITHOUT CHARGE ON THE SECURITIES AND EXCHANGE
 COMMISSIONS'S WEBSITE AT HTTP://WWW.SEC.GOV. WHEN AND IF COMPLETED, A
 DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE MAILED AND/OR MADE
 ELECTRONICALLY AVAILABLE TO STOCKHOLDERS OF BIOGEN IDEC INC. AND WILL ALSO
 BE AVAILABLE AT NO CHARGE AT HTTP://WWW.SEC.GOV. INFORMATION CONCERNING THE
 POTENTIAL PARTICIPANTS IS INCLUDED IN SCHEDULE 14A FILED BY MR. ICAHN AND
 HIS AFFILIATES WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 28,
 2008 AND IS AVAILABLE AT NO CHARGE AT HTTP://WWW.SEC.GOV.
 
 
 

SOURCE Icahn

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.